Beneficial effects of naringenin in liver diseases: Molecular mechanisms

• Published in: World journal of gastroenterology : WJG Vol. 24; no. 16; pp. 1679 - 1707
• Main Authors: Hernández-Aquino, Erika, Muriel, Pablo
• Format: Journal Article
• Language: English
• Published: United States Baishideng Publishing Group Inc 28.04.2018
• Subjects: Review; Cirrhosis; α-SMA; Flavonoids; Smads; Naringenin; JNK; Liver; Transforming growth factor; CCl4; Fibrosis; Hepatic stellate cells; MAPKs
• ISSN: 1007-9327; 2219-2840; 2219-2840
• DOI: 10.3748/wjg.v24.i16.1679

Liver diseases are caused by different etiological agents, mainly alcohol consumption, viruses, drug intoxication or malnutrition. Frequently, liver diseases are initiated by oxidative stress and inflammation that lead to the excessive production of extracellular matrix (ECM), followed by a progression to fibrosis, cirrhosis and hepatocellular carcinoma (HCC). It has been reported that some natural products display hepatoprotective properties. Naringenin is a flavonoid with antioxidant, antifibrogenic, anti-inflammatory and anticancer properties that is capable of preventing liver damage caused by different agents. The main protective effects of naringenin in liver diseases are the inhibition of oxidative stress, transforming growth factor (TGF-β) pathway and the prevention of the transdifferentiation of hepatic stellate cells (HSC), leading to decreased collagen synthesis. Other effects include the inhibition of the mitogen activated protein kinase (MAPK), toll-like receptor (TLR) and TGF-β non-canonical pathways, the inhibition of which further results in a strong reduction in ECM synthesis and deposition. In addition, naringenin has shown beneficial effects on nonalcoholic fatty liver disease (NAFLD) through the regulation of lipid metabolism, modulating the synthesis and oxidation of lipids and cholesterol. Moreover, naringenin protects from HCC, since it inhibits growth factors such as TGF-β and vascular endothelial growth factor (VEGF), inducing apoptosis and regulating MAPK pathways. Naringenin is safe and acts by targeting multiple proteins. However, it possesses low bioavailability and high intestinal metabolism. In this regard, formulations, such as nanoparticles or liposomes, have been developed to improve naringenin bioavailability. We conclude that naringenin should be considered in the future as an important candidate in the treatment of different liver diseases.